{"id":"leuprolide-acetate-for-injectable-suspension","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"5-15","effect":"Injection site reaction"},{"rate":"40-60","effect":"Decreased libido"},{"rate":"30-50","effect":"Erectile dysfunction"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-15","effect":"Bone pain (flare reaction)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leuprolide works by binding to GnRH receptors in the pituitary gland, initially causing a surge in gonadotropin release followed by sustained suppression of LH and FSH. This results in castration-level testosterone suppression in males and estrogen suppression in females, making it effective for hormone-dependent conditions. The injectable suspension formulation provides sustained release over weeks to months.","oneSentence":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:24.037Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT03649724","phase":"PHASE2","title":"The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-11-27","conditions":"Alzheimer Disease, Mild Cognitive Impairment","enrollment":180},{"nctId":"NCT06926933","phase":"PHASE4","title":"Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty","status":"RECRUITING","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2024-12-12","conditions":"CPP","enrollment":50},{"nctId":"NCT00687739","phase":"PHASE3","title":"Prevention of Obesity in Women Via Estradiol Regulation","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2008-05","conditions":"Obesity","enrollment":79},{"nctId":"NCT03899077","phase":"PHASE2","title":"Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP","status":"UNKNOWN","sponsor":"Cancer Research Antwerp","startDate":"2019-04-05","conditions":"Cancer of Prostate","enrollment":202},{"nctId":"NCT02993926","phase":"","title":"A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-06-24","conditions":"Central Precocious Puberty","enrollment":108},{"nctId":"NCT02427958","phase":"PHASE4","title":"A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08-07","conditions":"Central Precocious Puberty","enrollment":307},{"nctId":"NCT03085095","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-04-18","conditions":"Prostate Cancer","enrollment":1134},{"nctId":"NCT02122198","phase":"NA","title":"Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-09-08","conditions":"Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction","enrollment":17},{"nctId":"NCT03396978","phase":"NA","title":"The Influence of Gonadal Hormone Suppression on Adipocyte Lineage and the Microbiome","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2018-01-11","conditions":"Adipose Tissue, Microbiome, Menopause","enrollment":5},{"nctId":"NCT02452931","phase":"PHASE3","title":"Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty","status":"COMPLETED","sponsor":"Tolmar Inc.","startDate":"2015-08-31","conditions":"Precocious Puberty, Central","enrollment":64},{"nctId":"NCT01712230","phase":"NA","title":"Females, Aging, Metabolism, and Exercise","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-10","conditions":"Obesity","enrollment":47},{"nctId":"NCT02712320","phase":"PHASE3","title":"Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg","status":"COMPLETED","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2016-02","conditions":"Prostatic Neoplasms","enrollment":30},{"nctId":"NCT02234115","phase":"PHASE3","title":"Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma","status":"COMPLETED","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2014-08","conditions":"Prostatic Neoplasms","enrollment":137},{"nctId":"NCT00667446","phase":"PHASE3","title":"Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-12","conditions":"Precocious, Leuprolide Acetate, Luteinizing Hormone (LH)","enrollment":72},{"nctId":"NCT01161563","phase":"PHASE4","title":"Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2010-07","conditions":"Prostate Cancer","enrollment":118},{"nctId":"NCT00635817","phase":"PHASE3","title":"A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-06","conditions":"Puberty, Precocious","enrollment":84},{"nctId":"NCT00598312","phase":"PHASE3","title":"Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer","status":"COMPLETED","sponsor":"Oakwood Laboratories, LLC","startDate":"2007-04","conditions":"Prostate Cancer","enrollment":201},{"nctId":"NCT00076531","phase":"PHASE3","title":"Clinical Trial for Prostate Cancer","status":"COMPLETED","sponsor":"Oakwood Laboratories, LLC","startDate":"2003-12","conditions":"Prostate Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BLOOD CALCIUM DECREASED"},{"count":1,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":1,"reaction":"CELLULITIS"},{"count":1,"reaction":"CHOLELITHIASIS"},{"count":1,"reaction":"ELECTROCARDIOGRAM T WAVE INVERSION"},{"count":1,"reaction":"HYPERSENSITIVITY"},{"count":1,"reaction":"LYMPHATIC OBSTRUCTION"},{"count":1,"reaction":"LYMPHOEDEMA"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Leuprolide Acetate for Injectable Suspension","genericName":"Leuprolide Acetate for Injectable Suspension","companyName":"Oakwood Laboratories, LLC","companyId":"oakwood-laboratories-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production. Used for Advanced prostate cancer, Endometriosis, Uterine fibroids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}